Methylphenidate extended-release improved daily function in stable schizophrenia patients

People with schizophrenia spectrum disorder often struggle with daily tasks like holding a job or managing money. This trial asked if adding methylphenidate extended-release could help. The study involved 24 stable adults who received this medication for four weeks alongside their usual care. Researchers measured how well participants functioned using a virtual reality tool that simulates real-life tasks. They also checked cognitive skills and symptom severity. The results showed clear improvement in daily function scores. Participants who started with medication first saw gains early on. These gains lasted even after the initial medication phase ended. Symptom scores for delusions and social withdrawal also improved while on the drug. Cognitive tests showed better performance in specific areas like symbol coding. Importantly, none of the participants experienced a worsening of their psychosis. About three-quarters of the group continued taking the medication after the study. However, the study had a small number of participants and was open-label, meaning patients knew they were getting the drug. These factors mean the results should be viewed with some caution.